{"id":"aflibercept-mfolfiri3","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept is a recombinant fusion protein that acts as a VEGF trap, sequestering vascular endothelial growth factor and preventing tumor angiogenesis. When combined with mFOLFIRI (a modified regimen of 5-fluorouracil, leucovorin, and irinotecan), the regimen delivers both anti-angiogenic and direct cytotoxic effects against cancer cells. This combination approach targets both the tumor vasculature and the malignant cells themselves.","oneSentence":"Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:15.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with mFOLFIRI chemotherapy)"}]},"trialDetails":[{"nctId":"NCT04392479","phase":"PHASE3","title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","status":"UNKNOWN","sponsor":"Hôpital Franco-Britannique-Fondation Cognacq-Jay","startDate":"2020-09-02","conditions":"Cancer Colorectal, Metastasis","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZALTRAP- mFOLFIRI3"],"phase":"phase_3","status":"active","brandName":"Aflibercept-mFOLFIRI3","genericName":"Aflibercept-mFOLFIRI3","companyName":"Hôpital Franco-Britannique-Fondation Cognacq-Jay","companyId":"h-pital-franco-britannique-fondation-cognacq-jay","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy. Used for Metastatic colorectal cancer (in combination with mFOLFIRI chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}